CYPB - Cypress BioScience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: muddphudd who wrote (492)	2/7/1999 7:50:00 PM
From: Arthur Radley	Read Replies (1) of 586

Mudd, I don't have the newsletter handy as I was visiting a relative in another city this weekend and she subscribes to the Mayo letter. The article was about arthritis and the various treatments that are currently available such as Enbrel and that in mid-1999 they expected infliximab/Remilade to be approved by the FDA. It then had a small blurb about the prosorba column and the fact that it had been tested there at the clinic and other clinics and it concluded by saying.."it showed modest benefit for the patients using it".. or words to this affect. It was basically a two or three sentence report on the column. Wish I could add more.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next